Sagimet Biosciences (SGMT) Equity Ratio (2022 - 2026)

Sagimet Biosciences' Equity Ratio history runs 5 years deep, the most recent figure standing at 0.95 for Q1 2026.

• In Q1 2026, Equity Ratio changed 0.0% year-over-year to 0.95; the TTM figure through Mar 2026 stood at 0.95 (changed 0.0% YoY), while the FY2025 annual figure was 0.96, down 1.65% from the prior year.
• Equity Ratio was 0.95 for Q1 2026 at Sagimet Biosciences, down from 0.96 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.98 in Q1 2024 to a low of 9.23 in Q2 2023.
• Historically, Equity Ratio has averaged 0.34 across 5 years, with a median of 0.95 in 2025.
• The sharpest annual moves came in 2023 and 2025: Equity Ratio soared 116.64% in 2023, then fell 4.9% in 2025.
• A 5-year view of Equity Ratio shows it stood at 5.66 in 2022, then jumped by 116.64% to 0.94 in 2023, then rose by 3.26% to 0.97 in 2024, then declined by 1.65% to 0.96 in 2025, then decreased by 0.56% to 0.95 in 2026.
• The last three Equity Ratio figures came in at 0.95 (Q1 2026), 0.96 (Q4 2025), and 0.93 (Q3 2025), per Business Quant data.